Ride Share for Prostate Cancer Treatment Access
This study aims to improve access to prostate cancer treatment for Black men by addressing travel challenges. Researchers are testing if providing "Ride Share" services can help more men receive definitive treatment (surgery or radiation) within 90 days of their diagnosis. You may be able to join if you are a Black man, aged 22 or older, with intermediate- or high-risk prostate cancer, seeking treatment at the Mass General Brigham Prostate Cancer Outreach Clinic, and live in an area with high travel burden or have travel difficulties. The study's current status is unclear, and it plans to enroll 150 participants.
- Study design
- This interventional study plans to enroll 150 participants. It will pilot a trial offering ridesharing services and use a pre/post evaluation design with matched historical controls.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured within 90 days of diagnosis.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Increasing Access to Definitive Treatment for Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Quoc-Dien Trinh, MD,MBA · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Number of participants receiving definitive treatment within 90 days of diagnosisWithin 90 days of diagnosis
Surgery or radiation within 90 days of diagnosis, among men with prostate cancer diagnosed at localized or regional-intermediate stage. Investigators will identify patients with localized or regional intermediate- or high-risk PCa receiving definitive therapy (surgery and radiation to the prostate) within 90 days of diagnosis. Although there are no existing guidelines that recommend specific thresholds of timely receipt of treatment, initiating treatment within 90 days of diagnosis is considered enough time to account for logistics and the possible delay caused by seeking a second opinion. Registries only record the first treatment, so Investigators will rely on these measures to assess differences in travel burden to different locations, depending on the type of treatment. Investigators will estimate delays in treatment initiation by calculating the days between diagnosis and treatment initiation